Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 11:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 29,142 matching trials from the live ClinicalTrials.gov search.
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Hip or Knee (2)

NCT00863304
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 69 more
Conditions
Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma, Endometrial Carcinoma, Cancer of the Endometrium
Interventions
Niraparib
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
New Brunswick, New Jersey • Newark, New Jersey • Bay Shore, New York + 3 more
Conditions
Anesthesia
Interventions
Modified Time Principle Induction (MTPI) with rocuronium, RSI succinylcholine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Insulin Resistance, Prostate Cancer
Interventions
Pioglitazone 30 Mg Oral Tablet, Pioglitazone placebo tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Recruiting Phase 1Phase 2 Interventional

VS-6766+Abema+Fulv in Met HR+/HER- BC

NCT05608252
Conditions
Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
VS-6766, Abemaciclib, Fulvestrant
Drug
Lead sponsor
Adrienne G. Waks
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
Interventions
VERU-111, Enzalutamide, Abiraterone
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
40
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 36 more
Conditions
Chronic Hepatitis C
Interventions
SOF, RBV, Peg-IFN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
67
States / cities
Birmingham, Alabama • Bakersfield, California • Colton, California + 53 more
Conditions
Normal and Impaired Renal Function
Interventions
MTP-131
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Maimi, Florida
Conditions
Rectal Cancer
Interventions
Cetuximab, 5-Fluorouracil, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Weymouth, Massachusetts • Nashville, Tennessee
Conditions
Healthy Participants
Interventions
INCB123667, itraconazole, carbamazepine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
19 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Neoplasms
Interventions
PF-06664178
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Seattle, Washington
Conditions
Obesity
Interventions
sibutramine hydochloride monohydrate
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Conditions
Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers
Interventions
Entinostat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Sanfilippo Syndrome, Mucopolysaccharidosis III
Interventions
Epidiolex, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
4 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Conditions
Cancer
Interventions
Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
Drug · Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Gastrointestinal Stromal Tumors
Interventions
Imatinib, Fampridine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
La Jolla, California
Conditions
Coronary Artery Disease
Interventions
Cangrelor, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Cancer of the Breast
Interventions
IPI-504, Trastuzumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Palm Springs, California • Boca Raton, Florida • Davie, Florida + 6 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

NCT03831503
Conditions
Healthy Volunteers
Interventions
INO-A002, CELLECTRA® 2000, Dengue Fever Antibodies (IgG)
Biological · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Healthy Participants
Interventions
BMS-986166, Itraconazole, Extended Phenytoin Sodium, Gemfibrozil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Berlin, New Jersey
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model

NCT03383783
Conditions
Caries
Interventions
0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
Drug
Lead sponsor
Domenick Zero
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Interventions
TORL-1-23
Drug
Lead sponsor
TORL Biotherapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Lexington, Kentucky + 6 more
Conditions
Age Related Cataracts
Interventions
EDTA Ophthalmic Solution 2.6%, EDTA Ophthalmic Solution 1.3%, Saline Solution (Placebo)
Drug
Lead sponsor
Livionex Inc.
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
San Francisco, California • Overland Park, Kansas • Lutherville, Maryland + 3 more